Info
Meny
English
Logg inn
Søk etter prosjekter, resultater og personer
Søk etter prosjekter, resultater og personer
Cristin-prosjekt-ID:
546477
Registrert av:
REK
Sist endret:
28. september 2022, 10:03
Historikk
Cristin-prosjekt-ID:
546477
Registrert av:
REK
Sist endret:
28. september 2022, 10:03
Prosjekt
Kohortstudie om varigheten av BCG-vaksinens beskyttelse
prosjektleder
prosjektleder
Einar Heldal
ved Folkehelseinstituttet
prosjekteier / koordinerende forskningsansvarlig enhet
prosjekteier / koordinerende forskningsansvarlig enhet
Folkehelseinstituttet
Godkjenninger
Godkjenninger
Regionale komitéer for medisinsk og helsefaglig forskningsetikk (REK) - 2012/755
Kategorier
Kategorier
Helseprosjekttype
Annet studium
Tidsramme
Tidsramme
Avsluttet
Start:
1. april 2012
Slutt:
30. desember 2023
Beskrivelse
Beskrivelse
Engelsk
Norsk, bokmål
Tittel
Kohortstudie om varigheten av BCG-vaksinens beskyttelse
Populærvitenskapelig sammendrag
Tuberculosis (TB) remains a major preventable cause of morbidity. Bacillus Calmette Guerin (BCG) vaccines are widely used to protect against TB. Their efficacy shortly after vaccination has been demonstrated, but the duration of protection is not well known. This information is needed to inform BCG vaccination policies and can help to assess the cost of BCG vaccination against its effectiveness in the society. This study will measure the duration of BCG protection against TB and estimate changes in efficacy with time since vaccination. We will use historical population data to compare the frequency of TB occurrence in people who received the BCG and those who did not, at various period after vaccination.
Vis
fullstendig beskrivelse
Tittel
Kohortstudie om varigheten av BCG-vaksinens beskyttelse
Populærvitenskapelig sammendrag
Tuberculosis (TB) remains a major preventable cause of morbidity. Bacillus Calmette Guerin (BCG) vaccines are widely used to protect against TB. Their efficacy shortly after vaccination has been demonstrated, but the duration of protection is not well known. This information is needed to inform BCG vaccination policies and can help to assess the cost of BCG vaccination against its effectiveness in the society. This study will measure the duration of BCG protection against TB and estimate changes in efficacy with time since vaccination. We will use historical population data to compare the frequency of TB occurrence in people who received the BCG and those who did not, at various period after vaccination.
Vis
fullstendig beskrivelse
prosjektdeltakere
prosjektdeltakere
prosjektleder
Einar Heldal
Prosjektleder
ved Folkehelseinstituttet
Einar Heldal
Prosjektdeltaker
ved Avdeling for smittevern og vaksine ved Folkehelseinstituttet
1
-
2
av
2